Open AccessMorbidity and psychological impact of prostate biopsy: the future calls for a change
Author(s) -
Andrea Minervini,
Gianni Vittori,
Giampaolo Siena,
Marco Carini
Publication year - 2014
Publication title -
asian journal of andrology/asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.4103/1008-682x.126388
Subject(s) - medicine , biopsy , prostate cancer , prostate biopsy , prostate , urology , radiology , ultrasound , gynecology , general surgery , cancer
Currently transrectal ultrasound-guided prostate biopsy (TRUS-Bx) is one of the most common urological procedures, with more than 1 million performed per year in Europe and the United States. [1] Among patients undergoing TRUS-Bx, approximately one-third will receive a diagnosis of prostate cancer (PCa), while two-thirds receive a negative result on initial biopsy. Negative biopsy patients maintain an estimated risk of repeated biopsy of 12% at 1 year and 38% at 5 years. [2] Standard TRUS-Bx is likely to systematically miss significant tumors, particularly in the anterior and apical parts of the gland. [3] A crucial aim of urologists in the next decade is to increase the accuracy of the procedure and avoid the use of inappropriate biopsies